AER 002

Drug Profile

AER 002

Alternative Names: AER-002; Aerolytic; Bikunin - Aerovance; Inter-alpha-trypsin inhibitor light chain; Pulmolytic; SPINT2; Urinary trypsin inhibitor

Latest Information Update: 06 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer Aerovance
  • Class Anti-inflammatories
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Chronic obstructive pulmonary disease; Cystic fibrosis

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2011 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 06 Jan 2011 No development reported - Phase-II for Cystic fibrosis in Russia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top